VistaGen Therapeutics (VTGN) Stock Forecast, Price & News

VistaGen Therapeutics (NASDAQ:VTGN) Frequently Asked Questions

Is VistaGen Therapeutics a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for VistaGen Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VistaGen Therapeutics stock.
View analyst ratings for VistaGen Therapeutics or view top-rated stocks.

When is VistaGen Therapeutics' next earnings date?

VistaGen Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, July 5th 2022.
View our earnings forecast for VistaGen Therapeutics.

How were VistaGen Therapeutics' earnings last quarter?

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by $0.02. The business had revenue of $0.36 million for the quarter, compared to analyst estimates of $0.33 million. VistaGen Therapeutics had a negative net margin of 2,465.94% and a negative trailing twelve-month return on equity of 44.10%. During the same quarter in the prior year, the company earned ($0.05) EPS.
View VistaGen Therapeutics' earnings history.

What price target have analysts set for VTGN?

1 brokers have issued 1-year price objectives for VistaGen Therapeutics' stock. Their forecasts range from $9.00 to $9.00. On average, they anticipate VistaGen Therapeutics' share price to reach $9.00 in the next twelve months. This suggests a possible upside of 749.1% from the stock's current price.
View analysts' price targets for VistaGen Therapeutics or view top-rated stocks among Wall Street analysts.

Who are VistaGen Therapeutics' key executives?

VistaGen Therapeutics' management team includes the following people:

• Mr. Shawn K. Singh J.D., CEO & Director (Age 59, Pay $844.66k)
• Dr. H. Ralph Snodgrass Ph.D., Founder, Pres & Chief Scientific Officer (Age 72, Pay $547.69k) (LinkedIn Profile)
• Mr. Jerrold D. Dotson CPA, CPA, CFO, VP & Sec. (Age 69, Pay $484.62k)
• Dr. Mark A. Smith M.D., Ph.D., Chief Medical Officer (Age 67, Pay $547.69k)
• Ms. Ann Michelle Cunningham M.B.A., Chief Commercial Officer & Director (Age 54, Pay $30k)
• Mr. Mark Adrian McPartland, VP of Corp. Devel. (Age 56)
• Dr. Mark J. Ginski, Sr. VP and Head of Chemistry, Manufacturing & Controls (Age 50)

Who are some of VistaGen Therapeutics' key competitors?

Some companies that are related to VistaGen Therapeutics include Aclaris Therapeutics (ACRS), Chinook Therapeutics (KDNY), Avid Bioservices (CDMO), ImmunoGen (IMGN), Keros Therapeutics (KROS), ADVANZ PHARMA (CXRXF), Enanta Pharmaceuticals (ENTA), Acerus Pharmaceuticals (TRLPF), Merus (MRUS), Phibro Animal Health (PAHC), Mirum Pharmaceuticals (MIRM), Nuvation Bio (NUVB), Organogenesis (ORGO), Evolus (EOLS) and Verve Therapeutics (VERV).
View all of VTGN's competitors.

What other stocks do shareholders of VistaGen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VistaGen Therapeutics investors own include Highpower International (HPJ), AK Steel (AKS), Advaxis (ADXS), Matinas BioPharma (MTNB), Rite Aid (RAD), Sorrento Therapeutics (SRNE), Lithium Americas (LAC), ImmunoGen (IMGN), Yamana Gold (AUY) and CRISPR Therapeutics (CRSP).

What is VistaGen Therapeutics' stock symbol?

VistaGen Therapeutics trades on the NASDAQ under the ticker symbol "VTGN."

Who are VistaGen Therapeutics' major shareholders?

VistaGen Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.68%), Nicholas Investment Partners LP (2.21%), State Street Corp (1.75%), Northern Trust Corp (0.79%), Ghost Tree Capital LLC (0.64%) and Renaissance Technologies LLC (0.57%). Company insiders that own VistaGen Therapeutics stock include H Ralph Snodgrass and Jerrold Duane Dotson.
View institutional ownership trends for VistaGen Therapeutics.

Which institutional investors are selling VistaGen Therapeutics stock?

VTGN stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Ghost Tree Capital LLC, Goldman Sachs Group Inc., Northern Trust Corp, BlackRock Inc., Bank of New York Mellon Corp, Principal Financial Group Inc., and ClariVest Asset Management LLC.
View insider buying and selling activity for VistaGen Therapeutics or view top insider-selling stocks.

Which institutional investors are buying VistaGen Therapeutics stock?

VTGN stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Nicholas Investment Partners LP, Epiq Partners LLC, XTX Topco Ltd, Nisa Investment Advisors LLC, SG Americas Securities LLC, GSA Capital Partners LLP, and Charles Schwab Investment Management Inc..
View insider buying and selling activity for VistaGen Therapeutics or or view top insider-buying stocks.

How do I buy shares of VistaGen Therapeutics?

Shares of VTGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is VistaGen Therapeutics' stock price today?

One share of VTGN stock can currently be purchased for approximately $1.06.

How much money does VistaGen Therapeutics make?

VistaGen Therapeutics has a market capitalization of $218.92 million and generates $1.09 million in revenue each year. The company earns $-17.93 million in net income (profit) each year or ($0.360010) on an earnings per share basis.

How many employees does VistaGen Therapeutics have?

VistaGen Therapeutics employs 31 workers across the globe.

What is VistaGen Therapeutics' official website?

The official website for VistaGen Therapeutics is www.vistagen.com.

How can I contact VistaGen Therapeutics?

VistaGen Therapeutics' mailing address is 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (650) 577-3600, via email at [email protected], or via fax at 888-482-2602.